After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? (Q38826068)

6 September 2017

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? (English)

1 reference

6 September 2017

B Vergès

1

1 reference

PubMed ID

28431669

6 September 2017

B Charbonnel

series ordinal

2

1 reference

6 September 2017

1 April 2017

1 reference

6 September 2017

Diabetes and Metabolism

1 reference

6 September 2017

43 Suppl 1

1 reference

6 September 2017

2S3-2S12

1 reference

GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.

6 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Pathophysiology of diabetic dyslipidaemia: where are we?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Postprandial lipemia and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Exenatide exerts a potent antiinflammatory effect

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

The Cardiovascular Biology of Glucagon-like Peptide-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

The effect of liraglutide on endothelial function in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Insulin resistance and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2817%2930067-8

7 January 2021

10.1016/S1262-3636(17)30067-8

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

28431669